SCHEMBL6012882

SCHEMBL6012882

NC(=O)c1cc(Oc2ccc(N(C(N)=O)c3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 12/20 0.66
KDR P35968 5/20 0.52
BRAF P15056 5/20 0.52
RET P07949 3/20 0.52
GSK3B P49841 2/20 0.52
RIPK2 O43353 2/20 0.52
ABCB11 O95342 2/20 0.52
ABL1 P00519 2/20 0.52
HTR1A P08908 2/20 0.52
PDGFRB P09619 2/20 0.52
ADORA3 P0DMS8 2/20 0.52
KIT P10721 2/20 0.52
FGFR1 P11362 2/20 0.52
PDGFRA P16234 2/20 0.52
FLT1 P17948 2/20 0.52
MAOA P21397 2/20 0.52
EPHA1 P21709 2/20 0.52
TBXA2R P21731 2/20 0.52
EPHA2 P29317 2/20 0.52
TTK P33981 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27576013 0.92 RAF1 (0.59) RAF1KDRBRAFRETGSK3B
SCHEMBL694648 0.89 RAF1 (0.67) RAF1KDRBRAFRETGSK3B
Hydrochloric Acid SCHEMBL1702120 0.89 RAF1 (0.66) RAF1KDRBRAFRETGSK3B
SCHEMBL14480980 0.88 RAF1 (0.59) RAF1KDRBRAFRETGSK3B
Hydrochloric Acid SCHEMBL1702492 0.88 RAF1 (0.65) RAF1KDRBRAFRETGSK3B
SCHEMBL16143280 0.87 RAF1 (0.68) RAF1KDRBRAFRETGSK3B
SCHEMBL14481187 0.87 RAF1 (0.59) RAF1KDRBRAFRETGSK3B
SCHEMBL1702479 0.86 RAF1 (0.63) RAF1KDRBRAFRETGSK3B
Sulfuric Acid SCHEMBL2043327 0.86 RAF1 (0.63) RAF1KDRBRAFRETGSK3B
SCHEMBL13727752 0.85 RAF1 (0.54) RAF1KDRBRAFRETGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3845792-B2 2006-11-15 JP claimed
JP-2003526613-A 2003-09-09 JP claimed
CN-1341098-A Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER AG (US) 2002-03-20 CN claimed
EP-1140840-A1 -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS Bayer Corporation (US) 2001-10-10 EP claimed
WO-2000042012-A1 φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER CORPORATION (US) 2000-07-20 WO claimed
US-8618141-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE LLC (US) 2013-12-31 US disclosed
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY FLT4, FLT1, KDR RAF1 817/4885KDR 3/4885BRAF 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.